Información del artículo
El Texto completo está disponible en PDF
Biblografía
[1.]
D.C. Sweeney, G.S. Johnston.
Radioiodine therapy for thyroid cancer.
Endocrinol Metab Clin North Am, 24 (1995), pp. 803-839
[2.]
R.P. Fiedler.
Folicular carcinoma of the thyroid.
Malignant tumors of the thyroid. Clinical concepts and controversies, pp. 16-31
[3.]
R.L. Young, E.L. Mazzaferri, A.J. Rahe, S.G. Dorfman.
Pure follicular thyroid carcinoma: impact of therapy in 214 patients.
J Nucl Med, 21 (1980), pp. 733-737
[4.]
W.B. Laskin, P. James.
Occult papillary carcinoma of the thyroid with pulmonary metastases.
Hum Pathol, 13 (1983), pp. 83-85
[5.]
E.L. Mazzaferri.
Carcinoma of follicular epithelium: radioiodine and other treatment outcomes.
The thyroid: a fundamental and clinical text (7.a ed.), pp. 922-945
[6.]
R.J. Galloway, R.C. Smallridge.
Imaging in thyroid cancer.
J Clin Endocrinol Metab, 25 (1996), pp. 93-113
[7.]
N.A. Samaan, P.N. Schultz, R.C. Hickey, H. Goepfert, D.A. Jhonston, N.G. Ordoñez, et al.
The results of various modalities of treatment of well-differentiated thyroid carcinoma: a retrospective review of 1599 patients.
J Clin Endocrinol Metab, 75 (1992), pp. 714-720
[8.]
N. Altschuler, O.J. Degrossi, A. Fadel, S. Gutiérrez, I. Rozados, T. Watanabe.
Protocolo para el tratamiento complementario y seguimiento del carcinoma diferenciado de tiroides (CaDT) mediante el empleo de radioisótopos.
Rev Arg Endocrinol Metab, 33 (1996), pp. 175-182
[9.]
A.J. Dulgeroff, J.M. Hershman.
Medical therapy for differentiated thyroid carcinoma.
Endocr Rev, 15 (1994), pp. 500-515
[10.]
K. Ain.
Papillary thyroid carcinoma.
Endocrinol Metab Clin North Am, 24 (1995), pp. 711-760
[11.]
M. Bramley, J. Harrison.
Papillary microcarcinoma of the thyroid gland.
Br J Surg, 83 (1996), pp. 1674-1683
[12.]
B. Delgado, F. Botta, L. Mazzoni, L. Méndez, A. Pareyro de Morelli, H. Perinetti, et al.
Carcinoma diferenciado de tiroides. Clínicas Quirúrgicas de la Facultad de Medicina.
Montevideo: Librería Médica Editorial,, 11 (1992), pp. 1-158
[13.]
S.K. Grebe, I.D. Hay.
Follicular thyroid cancer.
Endocrinol Metab Clin North Am, 24 (1995), pp. 761-801
[14.]
National Cancer Institute PDQ Treatment Health Professionals. Thyroid Cancer. URL: http://cancernet.nci.nih.gov/
[15.]
S. Tezelman, O. Clark.
Current management of thyroid cancer advances in surgery, 28 (1995), pp. 191-221
[16.]
A. Schwartz, E. Friedman.
Surgery for well differentiated thyroid carcinoma.
Malignant tumors of the thyroid. Clinical concepts and controversies, pp. 65-85
[17.]
L. Tisell.
Role of lymphadenectomy in the treatment of differentiated thyroid carcinomas.
Br J Surg, 85 (1998), pp. 1025-1026
[18.]
E. Young, E. Soh, O. Clark.
Surgical considerations and approach to thyroid cancer.
Endocrinol Metab Clin North Am 1, 25 (1996), pp. 115-139
[19.]
T. Hefer, H. Joachims, A. Eitan, M. Munichor.
Are the morphology of the papillary thyroid carcinoma and the tumour's behaviour correlated?.
J Laryngol, 110 (1996), pp. 704-705
[20.]
C. Hedinger, E. Williams, L. Sobin.
WHO histological classification of thyroid tumor. A commentary on the second edition.
Cancer, 63 (1989), pp. 908-911
[21.]
V. Livolsi.
Papillary lesions of the thyroid, in livolsi. Surgical pathology of the thyroid. Major problems in pathology.
pp. 136-172
[22.]
S. Pilotti, P. Collini, M. Mariani, I. Bongarzone, P. Vigneri, S. Cipriani, et al.
Insular carcinoma A distinct de novo entity among follicular carcinomas of the thyroid gland.
Am J Surg Pathol, 31 (1997), pp. 1466-1473
[23.]
A. Sakamoto.
Poorly differentiated carcinoma of the thyroid.
Thyroid pathology. Current Topics in Pathology. 91, pp. 45-50
[24.]
A. Sakamoto, N. Kasai, H. Sugao.
Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a risk group of papillary and follicular carcinomas.
Cancer, 52 (1983), pp. 1849-1855
[26.]
W. Lang, H. Choritz, H. Hundenshagen.
Rick factors in follicular carcinomas. A retrospective follow up study covering a 14 year period with emphasis on morphological findings.
Am J Surg Pathol, 10 (1986), pp. 246-255
[27.]
E. Mazzaferri.
Papillary thyroid carcinoma. Factors influencing prognosis and current therapy.
Semin Oncol, 14 (1987), pp. 315-322
[28.]
J. Rodríguez, A. Moreno, P. Parrilla, J. Sola, T. Soria, F.J. Tebar, et al.
Papyllary thyroid microcarcinoma. Clinical study and prognosis. European Journal of Surgery.
Acta Chirurgica, 163 (1997), pp. 255-259
[29.]
J. Roai.
Follicular carcinoma.
Tumors of the thyroid gland. Atlas of tumor Pathology. Third series, pp. 49-63
[30.]
J.M. Hershman, H.E. Gordon.
Differentiated thyroid carcinoma. Wayne Bardin C. Current therapy in Endocrinology and Metabolism (6.a ed.).
pp. 122-126
[31.]
N. Farid, M. Zou, Y. Shi.
Genetics of follicular thyroid cancer.
Endocrinol Metab North Am, 24 (1995), pp. 865-883
[32.]
O. Gimm, H. Dralle.
Surgical strategies in papillary thyroid carcinoma.
Current topics in pathology, pp. 51-64
[33.]
B.A. Kenneth.
Papillary thyroid carcinoma. Etiology, assesment, and therapy.
Endocrinol Metab Clin North Am, 24 (1995), pp. 711-760
[34.]
J.E. Freitas.
Therapy of differentiated thyroid cancer.
Nucl Med Annual, pp. 883-1105
[35.]
J.R. Hurley, D.V. Becker.
The use of radioiodine in the management of thyroid cancer.
Nucl Med Annual, pp. 329-384
[36.]
H.M. Park, O.W. Perkins, J.W. Edmondson, R.B. Schnute, A. Manatunga.
Influence of diagnostic radioiodine on the uptake of ablation iodine 131.
Thyroid, 4 (1994), pp. 49-54
[37.]
J.C. Reynolds, J. Robbins.
The changing role of radioiodine in the management of differentiated thyroid cancer.
Semin Nucl, 27 (1997), pp. 152-164
[38.]
S.J. Mandel, G.A. Brent, P.R. Larsen.
Levothyroxine therapy in patients with thyroid disease.
Ann Intern Med, 119 (1993), pp. 492-502
[39.]
P.R. Larsen, F. DeRubertis, K. Yamashita, A. Dekker, J.B. Field.
In vitro demonstration of iodine-trapping defect but normal thyrotropin (TSH) responsiveness in benign and malignant “cold” thyroid nodules.
Trans Assoc Am Physicians, 85 (1972), pp. 309-316
[40.]
R.L. Segal.
Radioactive Iodine Treatment of Thyroid Carcinoma.
Maligment tumors of thyroid, pp. 101-111
[41.]
C.A. Spencer, J.S. Lopresti, A. Patel, R.B. Guttler, A. Eigen, D. Shen, et al.
Applications of a new chemiluminometric thyrotropin assay to subnormal measurement.
J Clin Endocrinol Metab, 70 (1990), pp. 453-460
[42.]
J.A. Franklyn, E.G. Black, J. Betteridge, M.C. Sheppard.
Comparison of second and third generation methods for measurement of serum thyrotropin in patiens with over hyperthyroidism, patients receiving thyroxine therapy, and those with nonthyroidal illness.
J Clin Endocrinol Metab, 78 (1994), pp. 1368-1371
[43.]
C.A. Spencer, M. Takeuchi, M. Kazarosyan, F. MacKenzie, G.J. Beckett, E. Wilkinson.
Interlaboratory/Intermethod differences in functional sensitivity of immunometric assays of thyrotropin (TSH) and impact on reliability of measurement of subnormal concentrations of TSH.
Clin Chem, 41 (1995), pp. 367-374
[44.]
The American Association of Clinical Endocrinologists.
AACE clinical practice guidelines for the management of thyroid carcinoma [en línea].
c, (1997),
[45.]
G. Hossein, F. Face.
Changing concepts in the diagnosis and management of thyroid nodules.
Endocrinol Metab Clin North AM, 26 (1997), pp. 777-800
[46.]
P. Bodlaender, J.R. Arjonilla, S.L. Twome.
Sensitive radioimmunological screening test for antithyroglobulin autoantibodies.
Clin Chem, 24 (1978), pp. 272-274
[47.]
U. Feldt-Rasmussen, K. Rasmussen.
Serum thyroglobulin (Tg) in presence of thyroglobulin auto-antibodies (Tg Ab). Clinical and methodological relevance of the interaction between Tg and Tg Ab in vitro and in vivo.
J Endocrinol Invest, 8 (1985), pp. 571-576
[48.]
A. Ligabue, M.C. Poggioli, A. Zacchini.
Interface of specific autoantibodies in the assessment of serum thyroglobulin.
J Nucl Biol Med, 37 (1993), pp. 273-279
[49.]
I.G. Ratcliffe, L. Ayoub, D. Pearson.
The measurement of serum thyroglobulin in the presence of thyroglobulin antibodies.
Clin Endocrinol, 15 (1981), pp. 507-518
[50.]
C.A. Spencer.
Recoveries cannot be used to authenticate thyroglobulin (Tg) measurements when sera contain Tg autoantibodies.
Clin Chem, 42 (1996), pp. 661-663
[51.]
C.A. Spencer, M. Takeuchi, M. Kazarosyma.
Current status and performance goals for serum thyroglobulin assays.
Clin Chem, 42 (1996), pp. 164-173
[52.]
C.A. Spencer, C.C. Wang.
Thyroglobulism measurement. Techniques, clinical benefits, and pitfalls.
Endocrinol Metab Clin North Am, 24 (1995), pp. 841-863
[53.]
D. McClellan, G. Francis.
Thyroid cancer in children pregnant women, and patients with Grave's disease.
Endocrinol Metab Clin North Am, 25 (1996), pp. 27-48
[54.]
D.C. Schwartz, G.S. Johnston.
Radioiodine therapy for thyroid cancer.
Endocrinol Metab Clin North Am, 24 (1995), pp. 803-839
[55.]
R. Russo, A. Coli, M. Cappagly, R. Leoncini, P. Poggi, A. Montepagani, et al.
Tc 99m Sestamibi scan in the follow up of differentiated thyroid carcinoma.
Eur J Nucl Med, 23 (1996),
[56.]
G. Meyer, U. Klene, R. Tiling, K. Stein, K. Hahn.
Tc 99m Sestamibi whole body scintigraphy: an usefull tool in the follow up of patients with differentiated thyroid carcinoma [resumen 12].
Eur J Nucl Med, 23 (1996), pp. S5
[57.]
B.R. Haugen, F. Pacini, C.H. Reiners, M. Schlumberger, P.W. Landenson, S.I. Sherman, et al.
A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer.
J Clin Endocrinol Metab, 84 (1999), pp. 3877-3885
[58.]
C. Fugazzola, L. Solbiati, M. Pregarz, I.A. Bergamo Andreis, G. Carbognin, et al.
Morphologic imaging of thyroid carcinoma.
Chirug Ital, 46 (1994), pp. 12-20
[59.]
A.W. Gretchen, M.D. Gooding.
Sonography of the thyroid and parathyroid.
Radiol Clin North Am, 31 (1993), pp. 967-989
[60.]
H. Hatabu, K. Kasagi, K. Yamamoto, Y. Iida, T. Misaki, A. Hidaks, et al.
Cystic papillary carcinoma of the thyroid gland: A new sonographic sign.
Clin Radiol, 43 (1991), pp. 121-124
[61.]
L. Solbiati, B. Arsizio, E. Ballarati, V. Cioffi, N. Poerio, F. Croce.
Microcalcifications: A clue in the diagnosis of thyroid malignancies.
Radiology, 177 (1990), pp. 140
[62.]
L. Solbiati, V. Cioffi, E. Ballarati.
UIltrasonography of the neck.
Radiol Clin North Am, 30 (1992), pp. 941-954
[63.]
E. Santos Martín, A. Saiz Ayala, E. Lozano Setién.
Técnicas de imagen para el estudio del espacio visceral del cuello. Tiroides y paratiroides.
Endocrinología, 46 (1999), pp. 123-137
[64.]
M.W. Ashcraft, A.J. Van Herle.
The comparative value fo serum thyroglobulin measurements and iodine 131 total body scans in the followup study of patients with treated differentiated thyroid cancer.
Am J Med, 71 (1981), pp. 806-814
[65.]
A. Kumar, D.H. Shah, U.R. Thakare.
Biochemical characterization of serum thyroglobulin from patients with bone metastases from follicular carcinoma of the thyroid.
Ind J Biochem Biophys, 28 (1991), pp. 198-205
[66.]
M. Ozata, S. Suzuki, T. Miyamoto, R.T. Liu, F. Fierro-Renoy, L.J. De Groot.
Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer.
J Clin Endocrinol Metab, 79 (1994), pp. 98-105
[67.]
F. Pacini, R. Lari, S. Mazzeo.
Diagnostic value fo a single serum thyroglobulin determination on and off thyroid suppression therapy in the follow-up of patients with differentiated thyroid cancer.
Clin Endocrinol, 23 (1985), pp. 405-411
[68.]
A.J. Van Herle, D.G. Brown.
Thyroglobulin in benign and malignant thyroid disease.
Thyroid disease: endocrinology, surgery, nuclear medicine and radiotherapy, pp. 473-484
[69.]
A.F. Cailleux, J.P. Travagli, M. Ricard, M. Schlumberger.
Is diagnostic Iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?.
J Clin Endocrinol Metab, 85 (2000), pp. 175-178
[70.]
M.E. O'Connell, M.A. Flower, P.J. Hinton.
Radiation dose assesmente in radioiodine therapy. Dose response relationship in differentiated thyroid carcinoma using quantitative scanning and PET.
Radiother Oncol, 28 (1993), pp. 16-26
[71.]
E.L. Mazzaferri, S.M. Jhiang.
Long-term impact of initial surgical and medical therapy on papillary and follicular thyroic cancer.
Am J Med, 97 (1994), pp. 418-428
[72.]
M.H. Bierwaltes.
Survival time and “cure” in papillary and follicular thyroid carcinoma with distant metastases. Statics following University of Michigan.
J Nucl Med, 25 (1984), pp. 1287-1293
[73.]
M. Schlumberger, O. Arcangioli, J.D. Piekarski, M. Tubiana, C. Parmentier.
Detection and treatment of lung metastases of differentiated thyroid carcinoma in patient normal chest × rays.
J Nucl Med, 29 (1988), pp. 179-204
[74.]
E. Lubin, S. Mefchlis-Frish, S. Zatz, A. Shimoni, K. Segal, A. Abraham, et al.
Serum Thyroglobulin and Iodine-131 hole – body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma.
J Nucl Med, 35 (1994), pp. 257-262
[75.]
F. Pacini, F. Lippi, N. Formica, R. Elisei, S. Anelli, C. Cecarelli, et al.
Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin.
J Nucl Med, 28 (1987), pp. 1888-1891
[76.]
J.D. Pineda, T. Lee, K. Ain, J.C. Reynolds, J. Robbins.
Tiodine-131 therapy for thyroid cancer in patients with elevated thyroglobulin and negative diagnostic scan.
J Clin Endocrinol Metab, 80 (1995), pp. 1488-1492
[77.]
E.L. Mazaferri.
Thyroid carcinoma: Papillary and follicular.
Endocrine tumors, pp. 278-333
[78.]
E.L. Mazzaferri.
Treating high thyroglobulin with radioiodine: a magic bullet or a shot in the dark?.
J Clin Endocrinol Metab, 580 (1995), pp. 1485-1487
[79.]
A.Z. Rudavsky, L.M. Freeman.
Treatment of scan-negative, thyroglobulin-positive metastatic thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormone.
J Clin Endocrinol Metab, 82 (1997), pp. 11-14
[80.]
C.A. Meier, L.E. Braverman, S.A. Ebner, I. Veronikis, G.H. Daniels, D.S. Ross, et al.
Diagnostic use of human recombinant thyrotropin in patient with thyroid carcinoma (phase I/II study).
J Clin Endoc Metab, 78 (1994), pp. 181-196
[81.]
E.L. Mazaferri.
Long-term outcome of patients with differentiated thyroid carcinoma: impact of therapy.
Rev Arg Endocrinol Metab, 36 (1999), pp. 17-23
[82.]
P.W. Ladenson, L.E. Braverman, E.L. Mazzaferri, F. Crucker-Davis, D.S. Cooper, J.R. Garber, et al.
Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patient with thyroid carcinoma.
N Engl J Med, 337 (1997), pp. 888-896
[83.]
S.S. Koong, J.C. Reynolds, E.G. Movius, A.M. Keenan, K.B. Ain, M.C. Lakshmanan, et al.
Lithium as a potential adjuvant to 131I therapy of metastatic, well diferentiated thyroid carcinoma.
J Clin Endocrinol Metab, 84 (1999), pp. 912-916
[84.]
F. Grünwald, C. Menzel, H. Bender, H. Palmedo, R. Otte, R. Fimmers, et al.
Redifferentiation therapy-induced radioiodine uptake in thyroid cancer.
J Nucl Med, 39 (1998), pp. 1903-1906
[85.]
F. Grünwald, E. Pakos, H. Bender, C. Menzel, R. Otte, H. Palmedo, et al.
Rediferentiation therapy with retinoic acid in follicular thyroid cancer.
J Nucl Med, 39 (1998), pp. 1555-1558
[86.]
D. Simon, J. Köehrle, C. Reiners, A. Boerner, C. Schmutzler, K. Mainz, et al.
Redifferentiation therapy-induced acid in follicular thyroid cancer.
J Nucl Med, 39 (1998), pp. 1555-1558
[87.]
D. Simon, J. Köehrle, C. Schmutzler, K. Mainz, C. Reiners, H.D. Röher.
Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid: basics and first clinical results.
Exp Clin Endocrinol Diabetes, 104 (1996), pp. 12-14
[88.]
E.L. Mazzaferri.
An overview of the management of papillary and follicular thyroid carcinoma.
Thyroid, 9 (1999), pp. 421-427
Copyright © 2001. Sociedad Española de Endocrinología y Nutrición